News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2020

23 November, 2020 Clarification regarding ownership changes in PledPharma News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
12 November, 2020 PledPharma publishes a supplement to the prospectus News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
11 November, 2020 Interim Report January 1-September 30, 2020 News English Regulatory MAR Report Interim Q3 IR Optional
10 November, 2020 NOTICE TO ATTEND EXTRAORDINARY GENERAL MEETING IN PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
6 November, 2020 Henrik Krook appointed VP Commercial Operations at PledPharma News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
5 November, 2020 PledPharma publishes prospectus and updated financial information in connection with fully guaranteed rights issue and the admission to trading of shares News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
28 October, 2020 Resolutions from extraordinary general meeting in PledPharma AB (publ) held on 28 October 2020 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
20 October, 2020 Nomination Committee appointed for the 2021 Annual General Meeting in PledPharma News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
5 October, 2020 Notice of Extraordinary general meeting in PledPharma AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
5 October, 2020 PledPharma carries out a fully guaranteed rights issue of approximately SEK 200 million in connection with the acquisition of Rare Thyroid Therapeutics News Corporate Action Shares Issuance English Regulatory MAR IR Optional
5 October, 2020 PledPharma to acquire Rare Thyroid Therapeutics, creating a new focused orphan drug development company News Corporate Action M&A English Regulatory MAR IR Optional
20 August, 2020 Half-Year report January-June 2020 News English Regulatory MAR VPML Report Interim Q2 IR Optional
30 July, 2020 Changes in PledPharma’s Board of Directors and committees News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
24 June, 2020 Marie-Louise Alamaa appointed interim CFO at PledPharma News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
26 May, 2020 CFO Yilmaz Mahshid leaves PledPharma News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
23 April, 2020 Kommuniké från årsstämman i PledPharma AB (publ) News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
22 April, 2020 Interim report January-March 2020 News English Regulatory MAR Report Interim Q1 IR Optional
6 April, 2020 PledPharma to close POLAR phase 3 program in the third quarter News Corporate Action Other English Regulatory MAR IR Optional
30 March, 2020 PledPharma’s 2019 annual report published News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
25 March, 2020 KALLELSE TILL ÅRSSTÄMMA I PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
1 March, 2020 PledPharma places dosing of patients in the POLAR program on hold News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-pledox
18 February, 2020 Year-end report January-December 2019 News English Regulatory MAR Report Interim Yearend IR Optional
23 January, 2020 PledPharma provides update on the clinical POLAR program, clinical hold in the US News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-pledox

2019

31 October, 2019 Trading in PledPharma's shares commences today on the Nasdaq Stockholm main market News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
29 October, 2019 PledPharma publishes prospectus in connection with the list change to Nasdaq Stockholm’s main market News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
PreviousNext

Calendar and upcoming reports

December 18, 2024
Investor Day (Stockholm & online)

February 26, 2025
Year-end Report Q4 2024 (7:00am CET)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]